GENELUX CORP (GNLX)
US36870H1032 - Common Stock
We assign a fundamental rating of 2 out of 10 to GNLX. GNLX was compared to 581 industry peers in the Biotechnology industry. GNLX scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. GNLX does not seem to be growing, but still is valued expensively.
1. Profitability
1.1 Basic Checks
In the past year GNLX has reported negative net income.
GNLX had a negative operating cash flow in the past year.
GNLX had negative earnings in each of the past 5 years.
In the past 5 years GNLX always reported negative operating cash flow.
1.2 Ratios
The Return On Assets of GNLX (-101.43%) is worse than 78.58% of its industry peers.
Looking at the Return On Equity, with a value of -145.29%, GNLX is doing worse than 64.59% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -101.43% | ||
| ROE | -145.29% | ||
| ROIC | N/A |
ROA(3y)-132.38%
ROA(5y)-169.81%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
GNLX does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
GNLX does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, GNLX has more shares outstanding
There is no outstanding debt for GNLX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
GNLX has an Altman-Z score of -8.11. This is a bad value and indicates that GNLX is not financially healthy and even has some risk of bankruptcy.
With a Altman-Z score value of -8.11, GNLX is not doing good in the industry: 73.40% of the companies in the same industry are doing better.
There is no outstanding debt for GNLX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -8.11 |
ROIC/WACCN/A
WACC7.85%
2.3 Liquidity
GNLX has a Current Ratio of 3.69. This indicates that GNLX is financially healthy and has no problem in meeting its short term obligations.
With a Current ratio value of 3.69, GNLX perfoms like the industry average, outperforming 40.59% of the companies in the same industry.
GNLX has a Quick Ratio of 3.69. This indicates that GNLX is financially healthy and has no problem in meeting its short term obligations.
GNLX has a Quick ratio (3.69) which is in line with its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.69 | ||
| Quick Ratio | 3.69 |
3. Growth
3.1 Past
The earnings per share for GNLX have decreased strongly by -508.25% in the last year.
The Revenue for GNLX has decreased by -98.46% in the past year. This is quite bad
EPS 1Y (TTM)-508.25%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-94.28%
Revenue 1Y (TTM)-98.46%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-100%
3.2 Future
GNLX is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 21.90% yearly.
GNLX is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 291.00% yearly.
EPS Next Y10.64%
EPS Next 2Y-9.02%
EPS Next 3Y4.47%
EPS Next 5Y21.9%
Revenue Next Year-97.75%
Revenue Next 2Y-41.42%
Revenue Next 3Y436.1%
Revenue Next 5Y291%
3.3 Evolution
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for GNLX. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for GNLX. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-9.02%
EPS Next 3Y4.47%
5. Dividend
5.1 Amount
No dividends for GNLX!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
GENELUX CORP
NASDAQ:GNLX (5/31/2024, 7:00:00 PM)
After market: 2.71 0 (0%)2.71
+0.06 (+2.26%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap73.17M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -101.43% | ||
| ROE | -145.29% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.01
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 3.69 | ||
| Quick Ratio | 3.69 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)-508.25%
EPS 3YN/A
EPS 5Y
EPS Q2Q%
EPS Next Y10.64%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)-98.46%
Revenue growth 3YN/A
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y